Breaking News Instant updates and real-time market news.

2016-10-06 08:42:14

WDAY

Workday

$92.05

1.56 (1.72%)

08:42

10/06/16

10/06

08:42

10/06/16

08:42

Palihapitiya sees Workday as $100B company in 10 years

Chamath Palihapitiya of Social Capital said at yesterday's Sohn San Francisco Investment Conference that Workday will be worth $100B in 10 years, according to CNBC. The provider of enterprise cloud applications has a current market capitalization just above $18B. The stock is up 1% to $93.00 in pre-market trading. Reference Link

11

Oct

12

Oct

WDAYWorkday

$92.05

1.56 (1.72%)

09/28/16

WEDB

09/28/16UPGRADETarget $82WEDBNeutral

Workday upgraded to Neutral from Underperform at Wedbush

Wedbush analyst Steve Koenig upgraded Workday to Neutral and raised its price target to $82 from $69 based on 2H 2016 sales potential, following a 1H which he things wasn't as good as generally perceived. Checks with integrators at Workday Rising yesterday suggest that 2H activity could be picking up, mirroring management's confidence and relaxed tone at Workday's analyst meeting. Koeing no longer sees failure to meaningfully beat and raise guidance for subscription revenue as a sufficient downside catalyst for Workday shares, based on the positive market reaction to Workday's 1Q and 2Q results.

09/28/16

09/28/16UPGRADE

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Workday (WDAY) upgraded to Neutral from Underperform at Wedbush with analyst Steve Koenig citing second-half 2016 sales potential, following a first-half which he thinks wasn't as good as generally perceived. 2. Dillard's (DDS) upgraded to Outperform from Neutral at Credit Suisse with analyst Michael Exstein citing the company's consistency in capital allocation and its valuation, which he says is at the low end of its historic trading range. 3. Cypress Energy (CELP) upgraded to Buy from Hold at Stifel analyst Michael Hoffman saying the CEO is upbeat on the company's outlook and its ability to maintain its distribution at current levels. 4. Huntington Bancshares (HBAN) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying the 15% pullback in the shares since the FirstMerit (FMER) deal was announced is overdone. 5. Hi-Crush Partners (HCLP) upgraded to Neutral from Sell at UBS with analyst Shneur Gershuni saying recent commentary from oil field service companies indicate an increase in sand demand and intensity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

09/30/16

OPCO

09/30/16NO CHANGETarget $100OPCOOutperform

Workday price target raised to $100 from $90 at Oppenheimer

Oppenheimer analyst Brian Schwartz raised his price target for Workday to $100 saying his customer survey makes him "increasingly comfortable" with the company's current business momentum. The analyst is "optimistic "about bookings and growth trends and sees low risk to estimates. Schwartz continues to view Workday as top 2016 pick with an Outperform rating.

10/03/16

ADAM

10/03/16NO CHANGETarget $110ADAMBuy

Workday price target raised to $110 from $98 at Canaccord

Canaccord analyst Richard Davis raised his price target on Workday to $110 from $98 as the company has grown into its current valuation and the stock will continue to advance on a sustainable basis in a bullish environment. Davis reiterated his Buy rating on Workday shares.

UP AFTER EARNINGS: Cintas (CTAS), up 2.9%... Micron (MU), up 2.8%. ALSO HIGHER: Editas Medicine (EDIT), up 3.1% after it received the EMA's orphan medicinal product designation for EDIT-101... Twitter (TWTR), up 1.8% after it said it will start testing longer, 280-character tweets with a small group. DOWN AFTER EARNINGS: Nike (NKE), down 3.2%. ALSO LOWER: Kornit Digital (KRNT), down 12.2% after it cut its third quarter revenue guidance... Westlake Chemical Partners (WLKP), down 8.3% after it filed to sell 4.5M units for limited partners... Intra-Cellular (ITCI), down 7.2% after it filed to sell $150M in common stock... Ascendis Pharma (ASND), down 4.3% after it announced an offering of $125M of ADSs.